announced on Thursday that the US Food and Drug Administration accepted its new drug application for review.
The UK-based specialty pharma company is seeking approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US.
Diurnal Group said the drug could potentially be approved in Q3 of 2020, citing a PDUFA date set by the FDA of 29 September 2020.
Martin Whitaker, CEO of Diurnal, commented: "We are pleased to announce that our NDA for Alkindi® Sprinkle in the US has been accepted for review by the FDA.”
“If approved, Alkindi® Sprinkle will provide a major breakthrough in the US as the only licensed treatment specifically designed for use in children with adrenal insufficiency, where there is a significant unmet patient need."
Shares in Diurnal were trading 1.79% higher at 28.5p during Thursday trading
Paediatric adrenal insufficiency is a condition characterized by deficiency in cortisol, an essential hormone in regulating growth, metabolism and the response to stress.
It is identified as an orphan disease in the US where there is estimated to have over 4000 sufferers under the age of 17.
Germany was the first country to launch Alkindi® in May 2018 to treat paediatric adrenal insufficiency, after being granted European marketing authorization in February 2018.
Follow News & Updates from Diurnal Group here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - London stocks were well into positive territory at the close on Friday, with banks pacing the advance after well-received results from Barclays, as investors shrugged off news that the UK's economic recovery was stalling.
Gunsynd, an investment firm operating within the natural resources sector, announced that it has invested C$0.25 million (around £0.146 million) into precious metals royalty and streaming company Empress Royalty Corp. The group said the move complements existing investments in the precious metals sector, adding new commodity exposure to silver.
Clinical stage drug development firm, Evgen Pharma, has been given the green light to kick-start its STAR trial which will investigate whether its lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.
Braveheart Investment Group, the AIM-listed investment firm, said its investee company, Pharm2Farm ("P2F"), will launch the sale of a new antiviral face mask that has a ‘kill rate’ of over 90% for up to 7 hours for COVID-19 by the end of the year.
London-listed Sensyne Health, the UK-based clinical AI company, announced that it has signed a research collaboration agreement with US pharmaceutical company Bristol Myers Squibb ("BMS"), marking its fourth successive partnership with a major pharma company.